This Entrepreneur's AI-Powered Dog Vaccine Could Revolutionize Cancer Treatment—Are You Prepared for the Shocking Truth?

In a remarkable convergence of technology and medicine, Sydney tech entrepreneur Paul Conyngham has turned his dog Rosie’s cancer battle into a groundbreaking case study for the potential of personalized medicine. In 2024, Conyngham discovered that Rosie, his beloved pet, had cancer. After undergoing chemotherapy and surgery, her tumors persisted, compelling Conyngham to seek alternative treatments.

With no medical background but extensive experience as an electrical and computing engineer and co-founder of Core Intelligence Technologies, Conyngham didn’t shy away from tackling the problem head-on. He enlisted the help of AI, specifically OpenAI’s ChatGPT, which pointed him towards immunotherapy options and directed him to the University of New South Wales Ramaciotti Center for Genomics. Convinced that he could find a solution, Conyngham paid for Rosie’s genomic sequencing to better understand her condition.

“I went to ChatGPT and came up with a plan on how to do this,” Conyngham explained, illustrating the unorthodox methods he employed to address Rosie’s deteriorating health. Utilizing advanced tools like AlphaFold, a protein-folding AI developed by Google’s DeepMind, he identified mutated proteins as potential targets for treatment. Although he found an immunotherapy treatment that seemed promising, the drug manufacturer declined to provide it.

Just when it appeared that all avenues were exhausted, Pall Thordarson, director of UNSW’s RNA Institute, stepped in. In a stunning feat of innovation, Thordarson was able to design a custom mRNA cancer vaccine using the data Conyngham had provided. This bespoke vaccine was developed in less than two months, marking a significant milestone as “the first time a personalized cancer vaccine has been designed for a dog,” according to Thordarson.

Rosie received her first injection of this revolutionary treatment in December 2024, followed by a booster in February 2025. Since then, most of her tumors have dramatically shrunk, and her overall health has improved. “In December, she had low energy because the tumors were creating a huge burden for her,” Conyngham said. “Six weeks post-treatment, I was at the dog park when she spotted a rabbit and jumped the fence to chase it.” While the tumors have not completely disappeared, the treatment has significantly enhanced Rosie’s quality of life.

Thordarson emphasized that Rosie’s case not only represents a breakthrough for veterinary medicine but also offers insights for human cancer treatment. “What Rosie is teaching us is that personalized medicine can be very effective, and done in a time-sensitive manner, with mRNA technology,” he said. Though there is no guarantee that Rosie will be fully cured, the treatment has afforded her more time, and Conyngham is grateful for that.

In a recent post on X (formerly Twitter), Thordarson noted that Rosie’s story exemplifies how technology can “democratize” the process of designing cancer vaccines. This project has not only taken the tech and medical communities by storm but has also sparked conversations about the future of cancer treatment. As the field of personalized medicine continues to evolve, Conyngham's journey underscores the potential for AI and biotechnology to transform what were once considered terminal diagnoses into manageable conditions.

Matt Shumer, co-founder and CEO of OthersideAI, expressed his fascination with Rosie’s story on social media, remarking, “This is what I mean when I say the world is going to get very weird, very soon. Expect more stories like this, each sounding increasingly more insane.”

As the boundaries between technology and healthcare blur, Rosie’s case serves as a beacon of hope for pet owners and medical professionals alike, showcasing the incredible possibilities that lie ahead when innovation meets compassion.